Background Treatment with cetuximab, a monoclonal antibody directed against the epidermal
growth factor receptor, improves overall and progression-free survival and preserves the …

Background Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth
factor receptor (EGFR), has activity against colorectal cancers that express EGFR. Methods …

Context Patients with periampullary adenocarcinomas undergo the same resectional
surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant …

Purpose The AVAGAST study showed that adding bevacizumab to chemotherapy in patients
with advanced gastric cancer improves progression-free survival and tumor response rate …

Purpose The oral mammalian target of rapamycin inhibitor everolimus demonstrated
promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, …

The intracellular signaling mechanisms that specify tissue-specific responses to the interleukin-6
(IL-6) family of cytokines are not well understood. Here, we evaluated the functions of …

Background Patients with peritoneal metastatic colorectal cancer have reduced overall survival
compared with patients with metastatic colorectal cancer without peritoneal involvement. …

… Tebbutt et al … An adjusted comparison was not possible for ATE, because no grades 3
to 4 events occurred in arm C. … Overall, 22%, 17%, and 15% of patients in arms C, CB …

Background Microsatellite-stable metastatic colorectal cancer is typically unresponsive to
immunotherapy. This phase 3 study was designed to assess atezolizumab plus cobimetinib in …

Background Right- and left-sided colon cancers (RC, LC) differ with respect to biology,
pathology and epidemiology. Previous data suggest a mortality difference between RC and LC. …